Search Results

You are looking at 41 - 50 of 449 items for :

  • Refine by Access: All x
Clear All
Full access

Daniel G. Coit and Anthony J. Olszanski

The incidence of melanoma has been steadily increasing over many decades, and melanoma patients will be “major consumers of health care for years to come,” said Chair of the NCCN Melanoma Panel Daniel G. Coit, MD, Co-Leader of the Melanoma Disease

Full access

Matthew Zibelman and Anthony J. Olszanski

metastatic melanoma. Molecular testing for BRAF and c-KIT mutational analyses were ordered but not immediately available. No primary lesions were ascertained on a full-body skin examination. Complete staging was performed with a whole body PET/CT and brain

Full access

Leslie A. Fecher and Keith T. Flaherty

Clinical Practice Guidelines in Oncology: Melanoma. NCCN Practice Guidelines in Oncology, Version 2, 2008 . Available at: http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf . Accessed January 20, 2009 . 4 Balch C Buzaid A Soong S

Full access

Senthil Damodaran, Ewa Mrozek, David Liebner, and Kari Kendra

of acute plaque rupture. 1 Although treatment of TC is largely supportive, negative inotropic agents such as β-blockers or calcium channel blockers can be beneficial. 7 This report presents a case of TC in a patient with metastatic melanoma

Full access

Andrea Maurichi, Francesco Barretta, Roberto Patuzzo, Rosalba Miceli, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Martina Angi, Francesco Baldo Lanza, Giuseppe Spadola, Mara Cossa, Francesco Nesa, Umberto Cortinovis, Laura Sala, Lorenza Di Guardo, Carolina Cimminiello, Michele Del Vecchio, Barbara Valeri, and Mario Santinami

Background Cutaneous melanoma may spread through the lymphatic circulation to the regional nodal basin, which means that the status of metastatic involvement of the sentinel node (SN) is one of the most important prognostic markers in melanoma

Full access

Tobin Strom, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod Sarnaik, James J. Mulé, Andy M. Trotti, Steven A. Eschrich, Vernon K. Sondak, and Louis B. Harrison

Background Node-positive cutaneous melanoma is heterogeneous, with 5-year survival rates ranging from 40% to 79%. 1 Many risk factors have been shown to be generally associated with regional recurrence following lymphadenectomy, including

Full access

Alan N. Houghton

Full access

In the year 2003, an estimated 54,200 new cases of melanoma will be diagnosed and some 7,600 patients will die of the disease. The lifetime risk of developing malanoma for someone born in the United States in the year 2000 may be as high as 1 in 82 for women and 1 in 58 for men. As with nearly all malignancies, the outcome of melanoma depends on the stage at presentation. Therefore, the panel cannot overemphasize the importance of early diagnosis and appropriate treatment.

For the most recent version of the guidelines, please visit NCCN.org

Full access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma: Cutaneous, published in this issue (page 439), include the latest updates. To assist readers interested in noting how the guidelines were updated, highlights of

Full access

Martin A. Weinstock and David E. Fisher

/print certificate. Learning Objectives Upon completion of this activity, participants will be able to: Identify the risk for melanoma and nonmelanoma skin cancers associated with artificial UV radiation Describe the physiologic effects of exposure to